DXS International (STU:7EE) Loans Receivable: €0.00 Mil (As of Apr. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:7EE DXS International PLC STU:7EE
39 GF Score
Price €0.01
GF Value €0.01
! 2 Warning Signs
View Full Analysis

What is DXS International Loans Receivable?

DXS International STU:7EE 39 Loans Receivable is €0.00 Mil as of Apr. 2025. GuruFocus rates STU:7EE with a GF Score™ of 39/100 and a GF Value™ of €0.01. The stock has 2 warning signs investors should review.

DXS International's Loans Receivable for the quarter that ended in Apr. 2025 was €0.00 Mil.

DXS International Loans Receivable Related Terms

DXS International Loans Receivable Historical Data

* Premium members only.

The historical data trend for DXS International's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DXS International Loans Receivable Chart

DXS International Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

DXS International Semi-Annual Data
Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:7EE
39GF Score
DXS International PLC STU:7EE
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DXS International Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of €0.00 Mil mean?
DXS International (STU:7EE) has a Loans Receivable of €0.00 Mil as of Apr. 2025. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on DXS International and its competitors.
Is DXS International's Loans Receivable too high?
DXS International's current Loans Receivable is €0.00 Mil. Overall, DXS International has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does DXS International's Loans Receivable compare to VEEV and BTSG?
DXS International's Loans Receivable of €0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Healthcare Providers & Services company?
A good Loans Receivable depends on the Healthcare Providers & Services industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on DXS International and its competitors. DXS International's current Loans Receivable is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DXS International stock overvalued right now?
DXS International (STU:7EE) has a current Loans Receivable of €0.00 Mil. The stock's GF Value™ is €0.01, compared to a current price of €0.01 — trading 10% above its estimated fair value. The current Loans Receivable is €0.00 Mil. DXS International's overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For DXS International (STU:7EE), the current Loans Receivable is €0.00 Mil as of Apr. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DXS International (STU:7EE) Overvalued in 2026?

Based on GuruFocus' analysis, DXS International stock appears to be overvalued. The current stock price of €0.01 is trading 10% above its estimated GF Value™ of €0.01.

Key valuation signals for STU:7EE:

  • Loans Receivable: €0.00 Mil
  • GF Value™: €0.01 vs. price of €0.01 (10% above fair value)
  • GF Score™: 39/100 with 2 warning signs

No single metric tells the full story. See the STU:7EE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DXS International Business Description

Other Exchanges DXSP:UK
Address 119 Saint Mary’s Road, Market Harborough, London, Leicestershire, GBR, LE16 7DT
DXS International PLC is engaged in the development and distribution of clinical decision support systems for General Practitioners, nurses, and retail pharmacies in the United Kingdom and South Africa. Its commercial activities include licensing DXS products to various ICBs, offering e-detailing opportunities to the pharmaceutical industry and the UK primary care sector, and licensing its technology to healthcare publishers. The company's products include BestPathway and Point-of-Care ExpertCare.
39GF Score

Get the complete analysis for STU:7EE

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.01
Price
€0.01
GF Value